. Author manuscript; available in PMC: 2017 May 1.

Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2016 Feb 29;25(5):807–814. doi: 10.1158/1055-9965.EPI-15-1044

Table 3.

Cost-effectiveness analysis of the see-and-treat strategy compared with usual care in two-way sensitivity analyses (with respect to biopsy-directed treatment adherence and disutility of LEEP treatment)

	ICER ($/QALY)
Disutility of LEEP treatment	Biopsy-directed treatment adherence = 30%	Biopsy-directed treatment adherence = 50%	Biopsy-directed treatment adherence = 90%
0 QALY	$38,077	$56,210	$423,433
0.01 QALY	$44,313	$70,774^*	Dominated
0.02 QALY	$52,992	$95,526	Dominated
0.03 QALY	$65,900	$146,899	Dominated
0.04 QALY	$87,120	$317,822	Dominated

Base-case

LEEP: loop electrosurgical excision procedure, ICER: incremental cost-effectiveness ratio.